BC001 / Buchang Pharma - LARVOL DELTA

March 17 evening announcements from listed companies [Google translation] (Sina Corp) - "Buchang Pharmaceutical (603858) announced on the evening of March 17 that Luzhou Buchang, the company's holding subsidiary, signed the 'Clinical Trial Service Contract' with Bonacia (Hefei) Pharmaceutical Technology Co., Ltd. Nacia Pharmaceuticals conducts the clinical trial technical service work of 'a randomized, double-blind, parallel controlled phase III study of BC001 combined with paclitaxel versus placebo-paclitaxel in the treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma who failed first-line standard treatment'."

Commercial • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology

Buchang Pharmaceuticals: Subsidiary Signs Distribution and License Agreement with LANCET for BC001 for Injection (Sina Corp) - "China Securities Network News (Reporter Zhang Pengfei) Buchang Pharmaceutical...announced on the evening of August 14 that its holding subsidiary Luzhou Buchang intends to sign a 'Distribution and Licensing Agreement' with the Russian company LANCET, authorizing LANCET to register, package and quality control the injectable BC001 in the Eurasian Economic Union and Uzbekistan as the holder of the product marketing license, and to commercialize the product as the exclusive distributor in the region. The announcement shows that BC001 is a recombinant anti-vascular endothelial growth factor receptor 2 (VEGFR2) fully human monoclonal antibody for injection. It is indicated for the treatment of cancer, including advanced gastric cancer and gastroesophageal junction adenocarcinoma."

Licensing / partnership • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

Buchang Pharmaceutical (603858.SH): The clinical trial application for new indications of "BC001 for injection" was accepted [Google translation] (Zhitong Finance) - "Zhitong Finance APP News, Buchang Pharmaceutical...announced that the company's controlled subsidiary Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. (referred to as 'Luzhou Buchang') has announced the clinical application of new indications for the research product 'BC001 for injection'. The trial application was accepted by the National Medical Products Administration and the 'Notification of Acceptance' was received. The planned indications are BC001 combined with PD-1 monoclonal antibody for the treatment of advanced or metastatic solid tumors, including but not limited to BC001 combined with sintilimab. Add XELOX as first-line treatment for HER-2-negative advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJ)."

New trial • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

Buchang Pharmaceutical: Clinical trial of BC001 drug for injection by its holding subsidiary was approved [Google translation] (Stockstar) - "Securities Times e Company News, Buchang Pharmaceutical...announced on the evening of November 8 that the clinical trial application for new indications of the company's controlled subsidiary Luzhou Buchang's research product 'BC001 for injection' has been approved by the State Food and Drug Administration and the 'Drug Clinical Trial Approval Notice' was received, and the proposed indication is for metastatic colorectal cancer that has failed or is intolerant to first-line and second-line standard treatments of BC001 combined with trifluridine and tipiracil tablets."

New trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Buchang Pharmaceutical: The application for clinical trials of new indications for the new varieties under research by the holding subsidiary has been accepted [Google translation] (Daily Economic News - NBD) - "Buchang Pharmaceutical...announced on the evening of August 30 that the company’s holding subsidiary Luzhou Buchang’s clinical trial application for the new indication of the product 'BC001 for injection' under research has been accepted by the State Food and Drug Administration and received the 'Notice of Acceptance', the planned indication is BC001 combined with trifluridine and tipiracil tablets for the treatment of metastatic colorectal cancer that has failed or is intolerant to first-line and second-line standard treatments."

New trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Buchang Pharmaceutical: Announcement of Shandong Buchang Pharmaceutical Co., Ltd. on the progress of the drug clinical trial of the holding subsidiary [Google translation] (Stockstar) - "Recently, Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. (hereinafter referred to as 'Luzhou Buchang'), a holding subsidiary of Shandong Buchang Pharmaceutical Co., Ltd. The application for the trial was accepted by the National Medical Products Administration and received the 'Notice of Acceptance'. The proposed indication is BC001 combined with Putalimab in the treatment of advanced solid tumors, including but not limited to BC001 and Putalimab combined with chemotherapy (XELOX, capecitabine, and oxaliplatin) for first-line treatment of HER-2-negative advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJ)."

New trial • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor